Cytolytic T cells play a major role in controlling herpes simplex virus type 2 (HSV-2) infections in humans. In an effort to more thoroughly evaluate the response to HSV-2 directly, ex vivo, we developed an enzyme-linked immunospot (ELISPOT) assay that utilized pools of overlapping synthetic peptides presented by autologous dendritic cells to purified CD8 ؉ T cells. Donor response rates to individual open reading frames (ORFs) ranged from fewer than 5% responding to as many as 70% responding, with the greatest frequency of responses (by ORF) being directed against UL39, UL25, UL27, ICP0, UL46, and UL47 in descending order of frequency. HSV-2-seropositive subjects responded to as few as 3 or as many as 46 of the 48 ORFs tested, with a median of 11 ORFs recognized. HLA-B*07 expression correlated with stronger responses overall that were directed primarily against UL49 and UL46. Cumulative precursor frequencies in the blood ranged from 500 to almost 6,000 HSV-2 spot-forming units/10 6 CD8 ؉ T cells. The magnitude and breadth of the response in the infected population were greater than previously appreciated. Whether this variability in the CD8 ؉ T-cell response within individuals is associated with the frequency of viral reactivation warrants further study.
Several lines of evidence support the importance of T-cell immunity in the resolution of herpes simplex virus (HSV) infections in humans.Patients with T-cell immune deficiencies, whether genetic or acquired, suffer more frequent reactivation and greater disease severity than immunocompetent persons (8). In animal models, deficiencies in CD8 ϩ T cells reduce viral clearance in neural tissue (16,18). In previous studies, we have shown that the reduction of viral shedding in lesional biopsies coincides with the appearance of HSV-2-specific cytolytic activity in lesions (13). These observations have largely been based upon qualitative assays of T-cell immunity. The last 5 years has seen the development of standardized assays to quantify T-cell responses to viral proteins. While a multitude of these studies have used whole viral antigens to evaluate responses to HSV-1 and HSV-2, little is known about the breadth and magnitude of the response to specific HSV proteins or about how these responses differ between individuals. To explore these issues, we initiated a study to define the predominant responses to specific HSV proteins among HSV-2-seropositive persons.(This work was presented in part at the 28th International Herpesvirus Workshop, Madison, Wis., 2003 and the 27th International Herpesvirus Workshop, Cairns, Australia, 2002.)
MATERIALS AND METHODSHuman subjects. Forty donors were recruited for this trial: 33 were attendees of the Virology Research Clinic at the University of Washington, Seattle, and 7 were recruited at Corixa Corp. Subjects electing to participate in the study gave informed consent. Thirty-seven of the donors were HSV-2 seropositive. Infection with HSV-1 and HSV-2 was diagnosed by type-specific immunoblot (1) or glycoprotein G-based (15) immuno...